



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH



PHARMACEUTICAL INSPECTION  
CONVENTION  
PHARMACEUTICAL INSPECTION  
CO-OPERATION SCHEME

19 September 2022  
EMA/INS/GMP/778340/2022  
GMP/GDP Inspectors Working Group (GMP/GDP IWG)

PS/INF 94/2022

## Concept Paper on the revision of Annex 11 of the guidelines on Good Manufacturing Practice for medicinal products – Computerised Systems

Agreed by EMA GMP/GDP IWG	31 October 2022
Agreed by PIC/S	15 November 2022
Start of public consultation	16 November 2022
End of consultation (deadline for comments)	16 January 2023

The proposed guideline will replace:

- Eudralex Volume 4: Annex 11 Computerised Systems
- for PIC/S participating authorities: PE 009-15: Annex 11 – Computerised Systems

Comments should be provided using this [template](#). The completed comments form should be sent to [ADM-GMDP@ema.europa.eu](mailto:ADM-GMDP@ema.europa.eu)

Keywords	GMP, medicinal product, annex 11
----------	----------------------------------

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

**Address for visits and deliveries** Refer to [www.ema.europa.eu/how-to-find-us](http://www.ema.europa.eu/how-to-find-us)

**Send us a question** Go to [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact) **Telephone** +31 (0)88 781 6000

An agency of the European Union



# 1. Introduction

1 This concept paper addresses the need to update Annex 11, Computerised Systems, of the Good  
2 Manufacturing Practice (GMP) guide. Annex 11 is common to the member states of the European Union  
3 (EU)/European Economic Area (EEA) as well as to the participating authorities of the Pharmaceutical  
4 Inspection Co-operation Scheme (PIC/S). The current version was issued in 2011 and does not give  
5 sufficient guidance within a number of areas. Since then, there has been extensive progress in the use  
6 of new technologies.

7  
8 Reasons for the revision of Annex 11 include, but are not limited to the following (in non-prioritised order  
9 and with references to existing sections in sharp brackets). More improvements may prove to be  
10 necessary as inputs will be received by the drafting group:

- 11 1. [New] The document should be updated to replace relevant parts of the [Q&A on Annex 11 and](#)  
12 [the Q&A on Data Integrity on the EMA GMP website](#).
- 13 2. [New] With regards to data integrity, Annex 11 will include requirements for 'data in motion' and  
14 'data at rest' (backup, archive and disposal). Configuration hardening and integrated controls  
15 are expected to support and safeguard data integrity; technical solutions and automation are  
16 preferable instead of manual controls.
- 17 3. [New] An update of the document with regulatory expectations to 'digital transformation' and  
18 similar newer concepts will be considered.
- 19 4. [Principle] The scope should not only cover where a computerised system "replaces of a manual  
20 operation", but rather, where it replaces 'another system or a manual process'.
- 21 5. [1] References should be made to ICH Q9.
- 22 6. [3.1] The list of services should include to 'operate' a computerised system, e.g. 'cloud' services.
- 23 7. [3.1] For critical systems validated and/or operated by service providers (e.g. 'cloud' services),  
24 expectations should go beyond that "formal agreements must exist". Regulated users should  
25 have access to the complete documentation for validation and safe operation of a system and  
26 be able to present this during regulatory inspections, e.g. with the help of the service provider.  
27 See also [Notice to sponsors and Q&A #9 on the EMA GCP website](#) and [Q&A on the EMA GVP](#)  
28 [website](#))
- 29 8. [3.3] Despite being mentioned in the Glossary, the term "commercial off-the-shelf products"  
30 (COTS) is not adequately defined and may easily be understood too broadly. Critical COTS  
31 products, even those used by "a broad spectrum of users" should be qualified by the vendor or  
32 by the regulated user, and the documentation for this should be available for inspection. The use  
33 of the term and the expectation for qualification, validation and safe operation of such (e.g.  
34 'cloud') systems should be clarified.
- 35 9. [4.1] The meaning of the term 'validation' (and 'qualification'), needs to be clarified. It should  
36 be emphasised that both activities consist of a verification of required and specified functionality  
37 as described in user requirements specifications (URS) or similar.
- 38 10. [4.1] Following a risk-based approach, system qualification and validation should especially  
39 challenge critical parts of systems which are used to make GMP decisions, parts which ensure  
40 product quality and data integrity and parts, which have been specifically designed or  
41 customised.
- 42 11. [4.4] It is not sufficiently clear what is implied by the sentence saying "User requirements should  
43 be traceable throughout the life-cycle". A user requirements specification, or similar, describing  
44 all the implemented and required GMP critical functionality which has been automated, and which  
45 the regulated user is relying on, should be the very basis for any qualification or validation of  
46 the system, whether performed by the regulated user or by the vendor. User requirements  
47 specifications should be kept updated and aligned with the implemented system throughout the  
48 system life-cycle and there should be a documented traceability between user requirements, any  
49 underlying functional specifications and test cases.
- 50 12. [4.5] It should be acknowledged and addressed that software development today very often  
51 follows agile development processes, and criteria for accepting such products and corresponding  
52 documentation, which may not consist of traditional documents, should be clarified.
- 53 13. [6] Guidelines should be included for classification of critical data and critical systems.
- 54 14. [7.1] Systems, networks and infrastructure should protect the integrity of GMP processes and  
55 data. Examples should be included of measures, both physical and electronic, required to protect  
56 data against both intentional and unintentional loss of data integrity.
- 57

- 58 15. [7.2] Testing of the ability to restore system data (and if not otherwise easily recreated, the  
59 system itself) from backup is critically important, but the required periodic check of this ability,  
60 even if no changes have been made to the backup or restore processes, is not regarded  
61 necessary. Long-term backup (or archival) to volatile media should be based on a validated  
62 procedure (e.g. through 'accelerated testing'). In this case, testing should not focus on whether  
63 a backup is still readable, but rather, validating that it will be readable for a given period.
- 64 16. [7.2] Important expectations to backup processes are missing, e.g. to what is covered by a  
65 backup (e.g. data only or data and application), what types of backups are made (e.g.  
66 incremental or complete), how often backups are made (all types), how long backups are  
67 retained, which media is used for backups, and where backups are kept (e.g. physical  
68 separation).
- 69 17. [8] The section should include an expectation to be able to obtain data in electronic format  
70 including the complete audit trail. The requirement to be able to print data may be reconsidered.
- 71 18. [9] An audit trail functionality which automatically logs all manual interactions on GMP critical  
72 systems, where users, data or settings can be manually changed, should be regarded as  
73 mandatory; not just 'considered based on a risk assessment'. Controlling processes or capturing,  
74 holding or transferring electronic data in such systems without audit trail functionality is not  
75 acceptable; any grace period within this area has long expired.
- 76 19. [9] The audit trail should positively identify the user *who* made a change, it should give a full  
77 account of *what* was changed, i.e. both the new and all old values should be clearly visible, it  
78 should include the full time and date *when* the change was made, and for all other changes  
79 except where a value is entered in an empty field or where this is completely obvious, the user  
80 should be prompted for the reason or rationale for *why* the change was made.
- 81 20. [9] It should not be possible to edit audit trail data or to deactivate the audit trail functionality  
82 for normal or privileged users working on the system. If these functionalities are available, they  
83 should only be accessible for system administrators who should not be involved in GMP  
84 production or in day-to-day work on the system (see 'segregation of duties').
- 85 21. [9] The concept and purpose of audit trail review is inadequately described. The process should  
86 focus on a review of the integrity of manual changes made on a system, e.g. a verification of the  
87 reason for changes and whether changes have been made on unusual dates, hours and by  
88 unusual users.
- 89 22. [9] Guidelines for acceptable frequency of audit trail review should be provided. For audit trails  
90 on critical parameters, e.g. setting of alarms in a BMS systems giving alarms on differential  
91 pressure in connection with aseptic filling, audit trail reviews should be part of batch release,  
92 following a risk-based approach.
- 93 23. [9] Audit trail functionalities should capture data entries with sufficient detail and in true time,  
94 in order to give a full and accurate picture of events. If e.g. a system notifies a regulated user  
95 of inconsistencies in a data input, by writing an error message, and the user subsequently  
96 changes the input, which makes the notification disappear; the full set of events should be  
97 captured.
- 98 24. [9] It should be addressed that many systems generate a vast amount of alarms and event data  
99 and that these are often mixed up with audit trail entries. While alarms and events may require  
100 their own logs, acknowledgements and reviews, this should not be confused with an audit trail  
101 review of manual system interactions. Hence, as a minimum, it should be possible to be able to  
102 sort these.
- 103 25. [11] The concept of configuration review should be added. Instead of taking onset in the number  
104 of known changes on a system (upgrade history), it should be based on a comparison of  
105 hardware and software baselines over time. This should include an account for any differences  
106 and an evaluation of the need for re-qualification/validation.
- 107 26. [12.1] The current section has only focus on restricting system access to authorised individuals;  
108 however, there are other important topics. In line with ISO 27001, a section on IT security should  
109 include a focus on system and data confidentiality, integrity and availability.
- 110 27. [12.1] The current version says that "Physical and/or logical controls should be in place to  
111 restrict access to computerised system to authorised persons". However, it is necessary to be  
112 more specific and to name some of the expected controls, e.g. multi-factor authentication,  
113 firewalls, platform management, security patching, virus scanning and intrusion  
114 detection/prevention.

- 115 28. [12.1] It should be specified that authentication on critical systems should identify the regulated  
116 user with a high degree of certainty. Therefore, authentication only by means of a 'pass card'  
117 might not be sufficient, as it could have been dropped and later found by anyone.
- 118 29. [12.1] Two important expectations for allocation of system accesses should be added either here  
119 or elsewhere; i.e. 'segregation of duties', that day-to-day users of a system do not have admin  
120 rights, and the 'least privilege principle', that users of a system do not have higher access rights  
121 than what is necessary for their job function.
- 122 30. [12.3] The current version says that "Creation, change, and cancellation of access authorisations  
123 should be recorded". However, it is necessary to go further than just recording who has access  
124 to a system. Systems accesses and roles should be continually managed as people assume and  
125 leave positions. System accesses and roles should be subject to recurrent reviews in order to  
126 ensure that forgotten and undesired accesses are removed.
- 127 31. [17] As previously mentioned (see 7.2), it is not sufficient to re-actively check archived data for  
128 accessibility, readability and integrity (it would be too late to find out if these parameters were  
129 not maintained). Instead, archival should rely on a validated process. Depending on the storage  
130 media used, it might be necessary to validate that the media can be read after a certain period.
- 131 32. [New] There is an urgent need for regulatory guidance and expectations to the use of artificial  
132 intelligence (AI) and machine learning (ML) models in critical GMP applications as industry is  
133 already implementing this technology. The primary focus should be on the relevance, adequacy  
134 and integrity of the data used to test these models with, and on the results (metrics) from such  
135 testing, rather than on the process of selecting, training and optimising the models.
- 136 33. [New] After this concept paper has been drafted and prepared for approval of the EMA GMP/GDP  
137 Inspectors Working Group and the PIC/S Sub-committee on GMDP Harmonisation, the FDA has  
138 released a draft guidance on Computer Software Assurance for Production and Quality System  
139 Software (CSA). This guidance and any implication will be considered with regards to aspects of  
140 potential regulatory relevance for GMP Annex 11.

## 141 **2. Discussion**

142 The current Annex 11 does not give sufficient guidance within a number of areas already covered, and  
143 other areas, which are becoming increasingly important to GMP, are not covered at all. The revised text  
144 will expand the guidance given in the document and embrace the application of new technologies which  
145 have gained momentum since the release of the existing version.

146 If possible, the revised document will include guidelines for acceptance of AI/ML algorithms used in  
147 critical GMP applications. This is an area where regulatory guidance is highly needed as this is not covered  
148 by any existing regulatory guidance in the pharmaceutical industry and as pharma companies are already  
149 implementing such algorithms.

## 152 **3. Recommendation**

153 The EMA GMP/GDP Inspectors Working Group and the PIC/S Sub-committee on GMDP Harmonisation  
154 jointly recommends that the current version of Annex 11, Computerised Systems, be revised according  
155 to this concept paper.

## 157 **4. Proposed timetable**

- 158 Preparation of draft concept paper – from October 2021  
159 Approval of draft concept paper by EMA GMP/GDP IWG – October 2022  
160 Release for consultation of draft concept paper (2 months consultation) – October 2022  
161 Deadline for comments on concept paper – December 2022  
162 Discussion in EMA GMP/GDP IWG and PIC/S Committee drafting group – from March 2023  
163 Proposed release for consultation of draft guideline (3 months consultation) – December 2024  
164 Deadline for comments on guideline – March 2025  
165 Adoption by EMA GMP/GDP IWG – March 2026  
166 Publication by European Community – June 2026  
167 Adoption by PIC/S Sub-committee on GMDP Harmonisation – September 2026

## 168 **5. Resource requirements for preparation**

169 A drafting group has been established by EMA GMP/GDP Inspectors Working Group and the PIC/S Sub-  
170 committee on GMDP Harmonisation with a rapporteur and supporting experts from other EU member  
171 regulatory authorities and from non-EU PIC/S participating authorities.

172  
173 It is expected that most of the work will be completed by email and by teleconference.

174  
175 The guideline will be discussed at GMP/GDP IWG and the PIC/S Committee as necessary and at other  
176 involved working parties and groups. Further discussions are expected with interested parties.

## 177 **6. Impact assessment (anticipated)**

178 The updated Annex 11 is intended to benefit both industry and regulators by clarifying expectations to  
179 areas already covered, by broadening these to areas not yet covered, and by pushing the adoption of a  
180 common approach between EU and non-EU regulatory authorities. Revision of Annex 11 will facilitate a  
181 better understanding of expectations to the use of computerised systems within manufacturing of  
182 medicinal products, and thereby, enhance the quality and safety of products and the integrity of data.

183  
184 No unnecessary adverse impact on industry with respect to either resources or costs is foreseen,  
185 although there is always a cost associated with being in compliance (or quality). The revision may require  
186 some systems and processes to be modified over a period of time.

## 187 **7. Interested parties**

- 188 • EMA GMP/GDP Inspectors Working Group
- 189 • PIC/S Committee, Sub-committee on GMDP Harmonisation
- 190 • National competent authorities of EU/EEA member states
- 191 • PIC/S participating authorities
- 192 • Pharmaceutical industry
- 193 • International societies and interest groups within pharmaceutical industry, e.g. ISPE GAMP

## 194 **8. References to literature, guidelines, etc.**

- 195 • EMA GMP Q&A on Annex 11 and Q&A on Data Integrity, [https://www.ema.europa.eu/en/human-](https://www.ema.europa.eu/en/human-regulatory/research-development/compliance/good-manufacturing-practice/guidance-good-manufacturing-practice-good-distribution-practice-questions-answers)  
196 [regulatory/research-development/compliance/good-manufacturing-practice/guidance-good-](https://www.ema.europa.eu/en/human-regulatory/research-development/compliance/good-manufacturing-practice/guidance-good-manufacturing-practice-good-distribution-practice-questions-answers)  
197 [manufacturing-practice-good-distribution-practice-questions-answers](https://www.ema.europa.eu/en/human-regulatory/research-development/compliance/good-manufacturing-practice/guidance-good-manufacturing-practice-good-distribution-practice-questions-answers)
- 198 • EMA GCP Guideline on computerised systems and electronic data in clinical trials (draft),  
199 EMA/226170/2021, [https://www.ema.europa.eu/en/documents/regulatory-procedural-](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guideline-computerised-systems-electronic-data-clinical-trials_en.pdf)  
200 [guideline/draft-guideline-computerised-systems-electronic-data-clinical-trials\\_en.pdf](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guideline-computerised-systems-electronic-data-clinical-trials_en.pdf)
- 201 • EMA GCP Q&A no. 8, 9, and Notice to sponsors on validation and qualification of computerised  
202 systems used in clinical trials on [https://www.ema.europa.eu/en/human-regulatory/research-](https://www.ema.europa.eu/en/human-regulatory/research-development/compliance/good-clinical-practice/ga-good-clinical-practice-gcp)  
203 [development/compliance/good-clinical-practice/ga-good-clinical-practice-gcp](https://www.ema.europa.eu/en/human-regulatory/research-development/compliance/good-clinical-practice/ga-good-clinical-practice-gcp)
- 204 • EMA GVP Q&A on Level of validation/qualification needed to be performed by a MAH when using an  
205 electronic system previously qualified by a provider [https://www.ema.europa.eu/en/human-](https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/compliance/coordination-pharmacovigilance-inspections)  
206 [regulatory/marketing-authorisation/compliance/coordination-pharmacovigilance-inspections](https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/compliance/coordination-pharmacovigilance-inspections)  
207